

BILH Prioritization Framework for COVID-19 Ambulatory Therapeutics

Tiers	
1	Severe immunosuppression
2	Unvaccinated and age ≥ 75 years
3	Unvaccinated and any other specified risk factors for progression to severe illness (see below)
4	Vaccinated and age ≥ 75 years
5	Vaccinated and any other specified risk factors for progression to severe illness (see below)
Sub tiers	
	Any of the following: <ul style="list-style-type: none"> • Pregnancy (and up to 6-weeks post-partum) • BMI ≥35 kg/m² • Social Vulnerability Index (Top Quartile) • Moderate immunosuppression [applies to tiers 2-5] • Completion of COVID-19 vaccine primary series but has not yet completed all recommended doses (e.g., third dose or booster) [applies only to tiers 4 and 5]
A	• Age ≥ 65 [applies only to tiers 1, 3 and 5]
B	Any other specified risk factors for progression to severe illness (see below)

v1.11.22

As approved by:

BILH Drug Shortage Task Force for COVID-19 Ambulatory Therapeutics 1.11.22

BILH COVID-19 Treatment Collaborative 1.13.22

COVID-19 Vaccination Status Tier & Sub-tier Definitions:

- COVID-19 Vaccine Primary Series: 2-doses of mRNA vaccine (Pfizer-BioNTech or Moderna) or 1-dose of J&J/Janssen
- Unvaccinated – Has NOT completed any COVID-19 vaccine primary series
- Vaccinated – Has completed any COVID-19 vaccine primary series
- Unboosted Sub Tier – Has completed any COVID-19 vaccine primary series but has not yet completed all recommended doses (e.g. receipt of additional dose for moderate-severe immunosuppression or booster for all).
 - This does NOT include boosters if ≥ 5 months has not elapsed since completion of primary series or additional dose for individuals with moderate-severe immunosuppression

Categories of Severe and Moderate Immunosuppression

Risk Factors for Progression to Severe COVID-19:

<u>Risk Factors for Progression to Severe COVID-19</u>
Age ≥ 65 years
Cardiovascular disease or hypertension
Chronic kidney disease
Chronic liver disease
Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis and pulmonary hypertension)
Diabetes
High Risk Body-Mass Index (BMI): <ul style="list-style-type: none"> • 25-30 kg/m² AND not fully vaccinated with primary 1-2 dose series (no vaccination or series completed less than 2 weeks prior) • >30 kg/m² regardless of vaccination status
Medical-related technological dependence (e.g. tracheostomy, gastrostomy, or positive pressure ventilation [not related to COVID 19])
<u>Mild-severely immunocompromising health conditions</u>
Neurodevelopmental disorders (e.g. cerebral palsy, genetic/metabolic syndromes, severe congenital anomalies)
Pregnancy and up to 6 weeks post-partum
Race/ethnicity that is associated with a higher risk of hospitalization or death from COVID-19, including Black or African American, Hispanic or Latinx, American Indian or Alaska Native
Sickle cell disease or other hemoglobinopathy